AR043670A1 - Composicion farmaceutica que contiene lactato y usos de la misma - Google Patents
Composicion farmaceutica que contiene lactato y usos de la mismaInfo
- Publication number
- AR043670A1 AR043670A1 ARP040100933A ARP040100933A AR043670A1 AR 043670 A1 AR043670 A1 AR 043670A1 AR P040100933 A ARP040100933 A AR P040100933A AR P040100933 A ARP040100933 A AR P040100933A AR 043670 A1 AR043670 A1 AR 043670A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition containing
- per liter
- millimoles per
- pharmaceutical composition
- lactate
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 4
- 235000014655 lactic acid Nutrition 0.000 abstract 2
- 239000004310 lactic acid Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000014644 Brain disease Diseases 0.000 abstract 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010053159 Organ failure Diseases 0.000 abstract 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000009429 distress Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
Abstract
Composición farmacéutica que contiene entre 250 y 2400 milimoles por litro de lactato o ácido láctico, entre 2 y 10 milimoles por litro del catión potasio y optativamente entre 2 y 5 milimoles por litro del catión calcio; uso farmacéutico de esta composición y uso farmacéutico de una composición que contiene una concentración de ácido láctico o lactato que comprende entre 250 y 2400 milimoles por litro. Para el tratamiento de una afección o enfermedad seleccionada del grupo formado por enfermedades cardiovasculares, trastornos cerebrales, insuficiencia de órganos, obesidad, resucitación y distres nemodinámico agudo debido a razones médicas y cirugía.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ID20030213 | 2003-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043670A1 true AR043670A1 (es) | 2005-08-03 |
Family
ID=33397627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100933A AR043670A1 (es) | 2003-05-01 | 2004-03-22 | Composicion farmaceutica que contiene lactato y usos de la misma |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20080125488A1 (es) |
| EP (2) | EP1617834B1 (es) |
| JP (1) | JP5037937B2 (es) |
| KR (1) | KR101076059B1 (es) |
| CN (1) | CN1777416B (es) |
| AR (1) | AR043670A1 (es) |
| AT (1) | ATE340568T1 (es) |
| AU (1) | AU2004233904B2 (es) |
| BR (1) | BRPI0409867A (es) |
| CA (1) | CA2523740C (es) |
| CY (1) | CY1105880T1 (es) |
| DE (1) | DE602004002585T2 (es) |
| DK (1) | DK1617834T3 (es) |
| EA (2) | EA013846B1 (es) |
| ES (1) | ES2274438T3 (es) |
| IL (1) | IL171721A (es) |
| MA (1) | MA27845A1 (es) |
| MX (1) | MXPA05011532A (es) |
| MY (1) | MY140382A (es) |
| NO (1) | NO20055652L (es) |
| NZ (1) | NZ543201A (es) |
| PL (1) | PL1617834T3 (es) |
| PT (1) | PT1617834E (es) |
| SG (1) | SG160217A1 (es) |
| SI (1) | SI1617834T1 (es) |
| TN (1) | TNSN05275A1 (es) |
| TW (1) | TWI290045B (es) |
| UA (1) | UA86937C2 (es) |
| WO (1) | WO2004096204A1 (es) |
| ZA (1) | ZA200509684B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0621528A2 (pt) * | 2006-04-03 | 2011-12-13 | Innogene Kalbiotech Pte Ltd | composição farmacêutica contendo lactato e cálcio, e usos da mesma |
| ES2482190T3 (es) | 2007-03-30 | 2014-08-01 | Laccure Ab | Uso de oligómeros de ácido láctico en el tratamiento de infecciones ginecológicas |
| CN108434126B (zh) | 2009-03-26 | 2021-11-19 | 普马特里克斯营业公司 | 治疗肺病的干粉配方与方法 |
| BRPI1013872A2 (pt) * | 2009-03-26 | 2018-06-19 | Pulmatrix Inc | formulações de citrato de cálcio e lactato de cálcio para alteração de propriedades biofísicas do revestimento da mucosa |
| AU2011296343B2 (en) | 2010-08-30 | 2015-12-10 | Pulmatrix Operating Company, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| US20130164338A1 (en) | 2010-08-30 | 2013-06-27 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| ES2710537T3 (es) | 2010-09-29 | 2019-04-25 | Pulmatrix Operating Co Inc | Polvos secos catiónicos |
| CN107096014B (zh) | 2010-09-29 | 2022-07-15 | 普马特里克斯营业公司 | 吸入用单价金属阳离子干粉剂 |
| ES2396650B2 (es) * | 2011-07-21 | 2013-07-16 | Universidad Complutense De Madrid | Uso de una composición en la elaboración de una solución de diálisis para el tratamiento de las enfermedades cerebrovasculares mediante diálisis peritoneal. |
| CN107596518B (zh) | 2012-02-29 | 2021-04-23 | 普马特里克斯营业公司 | 可吸入干粉剂 |
| BR112014027983B1 (pt) | 2012-05-08 | 2022-05-24 | Aeromics, Inc | Uso de inibidores de aquaporina seletivos |
| US10660869B2 (en) * | 2012-08-01 | 2020-05-26 | Purac Biochem B.V. | Lactate powder and method for the preparation thereof |
| US9897609B2 (en) | 2012-10-25 | 2018-02-20 | Run Them Sweet, LLC | Systems and apparatus to estimate nutritional needs of human and other patients and to support such nutritional needs |
| US9232815B2 (en) | 2012-10-25 | 2016-01-12 | Run Them Sweet, LLC | Blood lactate range targets and nutritional formulations and protocols to support patients |
| US9500657B2 (en) | 2012-10-25 | 2016-11-22 | Run Them Sweet Llc | Formulations containing labels for medical diagnostics |
| EP2769630B1 (en) | 2013-02-26 | 2016-04-27 | Purac Biochem N.V. | Improved nisin production process |
| EP2754356A1 (en) | 2013-01-15 | 2014-07-16 | Purac Biochem N.V. | Improved nisin production process |
| AU2014248455B2 (en) | 2013-04-01 | 2018-12-06 | Pulmatrix Operating Company, Inc. | Tiotropium dry powders |
| RU2691951C2 (ru) | 2013-11-06 | 2019-06-19 | Аэромикс, Инк. | Новые составы |
| WO2015182815A1 (ko) * | 2014-05-26 | 2015-12-03 | 한국생명공학연구원 | Ndrg3 발현 또는 활성 촉진제를 유효성분으로 함유하는 허혈성 질환 예방 및 치료용 약학적 조성물 |
| CA3026631C (en) | 2016-07-07 | 2024-03-26 | Dsm Ip Assets B.V. | Process for obtaining a rapeseed protein isolate and protein isolate thereby obtained |
| US10124021B2 (en) * | 2016-12-23 | 2018-11-13 | Andrew L. Gostine | Intravenous fluid |
| WO2020163654A1 (en) * | 2019-02-06 | 2020-08-13 | Paul Leo Mcgrane | Biologically modified vascular grafts for improved bypass surgery outcomes |
| EP4093507A4 (en) * | 2020-01-24 | 2024-02-28 | Barkey, Daniel, Q. | COMPOSITIONS AND METHODS FOR WEIGHT LOSS |
| JP2025500933A (ja) * | 2021-12-16 | 2025-01-15 | アルヴィアラス バイオ，インコーポレイテッド | 慢性肺疾患の治療のための吸入可能又は摂取可能な乳酸組成物 |
| CN116531358A (zh) * | 2023-06-06 | 2023-08-04 | 中国医科大学附属第一医院 | 含乳酸盐缓冲体系在制备心力衰竭治疗药物中的应用 |
| EP4502147A1 (en) | 2023-07-31 | 2025-02-05 | M2Rlab SL | Method for the polarization of cells to a new m2 phenotype and uses of said m2-polarized cells |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987003808A1 (en) * | 1985-12-18 | 1987-07-02 | Veech Richard L | Fluid therapy with l-lactate and/or pyruvate anions |
| EP0441119A3 (en) * | 1990-01-09 | 1992-10-14 | Richard D. Levere | The use of l-arginine in the treatment of hypertension and other vascular disorders |
| US5248507A (en) * | 1991-05-31 | 1993-09-28 | Board Of Regents, The University Of Texas System | Hypertonic isochloremic formulation for circulatory shock |
| JPH05255092A (ja) * | 1992-03-17 | 1993-10-05 | Kyowa Hakko Kogyo Co Ltd | 腸管洗浄用組成物 |
| DE69426879T2 (de) * | 1993-06-04 | 2001-10-18 | Biotime, Inc. | Plasma-artige lösung |
| US6306828B1 (en) * | 1995-04-06 | 2001-10-23 | Baxter International, Inc. | Enantiomerically-enhanced nutritional energy substrates |
| JPH0940554A (ja) * | 1995-08-03 | 1997-02-10 | Nissho Corp | グルタミンを含む輸液及びその製造方法 |
| WO1998008500A1 (en) * | 1996-08-26 | 1998-03-05 | Board Of Regents, The University Of Texas System | Hypertonic arginine compositions and methods |
| US6436444B1 (en) * | 1997-09-26 | 2002-08-20 | Ecolab Inc. | Acidic aqueous chlorite teat dip providing shelf life sanitizing capacity and tissue protection |
| CN1068778C (zh) * | 1998-05-15 | 2001-07-25 | 赵超英 | 救治用的药物组合物及其制备方法 |
| RU2136293C1 (ru) * | 1998-08-04 | 1999-09-10 | Открытое акционерное общество "Биохимик" | Способ получения заменителя плазмы крови |
-
2004
- 2004-03-22 EA EA200801073A patent/EA013846B1/ru not_active IP Right Cessation
- 2004-03-22 CA CA2523740A patent/CA2523740C/en not_active Expired - Fee Related
- 2004-03-22 SI SI200430136T patent/SI1617834T1/sl unknown
- 2004-03-22 MX MXPA05011532A patent/MXPA05011532A/es active IP Right Grant
- 2004-03-22 SG SG200717319-8A patent/SG160217A1/en unknown
- 2004-03-22 DE DE602004002585T patent/DE602004002585T2/de not_active Expired - Lifetime
- 2004-03-22 AR ARP040100933A patent/AR043670A1/es not_active Application Discontinuation
- 2004-03-22 AT AT04722501T patent/ATE340568T1/de active
- 2004-03-22 BR BRPI0409867-6A patent/BRPI0409867A/pt not_active IP Right Cessation
- 2004-03-22 PL PL04722501T patent/PL1617834T3/pl unknown
- 2004-03-22 UA UAA200511417A patent/UA86937C2/ru unknown
- 2004-03-22 PT PT04722501T patent/PT1617834E/pt unknown
- 2004-03-22 MY MYPI20040998A patent/MY140382A/en unknown
- 2004-03-22 CN CN2004800110612A patent/CN1777416B/zh not_active Expired - Fee Related
- 2004-03-22 EP EP04722501A patent/EP1617834B1/en not_active Expired - Lifetime
- 2004-03-22 WO PCT/SG2004/000066 patent/WO2004096204A1/en not_active Ceased
- 2004-03-22 NZ NZ543201A patent/NZ543201A/en not_active IP Right Cessation
- 2004-03-22 JP JP2006508059A patent/JP5037937B2/ja not_active Expired - Fee Related
- 2004-03-22 ES ES04722501T patent/ES2274438T3/es not_active Expired - Lifetime
- 2004-03-22 AU AU2004233904A patent/AU2004233904B2/en not_active Ceased
- 2004-03-22 EP EP06121128A patent/EP1759695A1/en not_active Withdrawn
- 2004-03-22 DK DK04722501T patent/DK1617834T3/da active
- 2004-03-22 US US10/555,196 patent/US20080125488A1/en not_active Abandoned
- 2004-03-22 EA EA200501675A patent/EA010948B1/ru not_active IP Right Cessation
- 2004-03-23 TW TW093107705A patent/TWI290045B/zh not_active IP Right Cessation
-
2005
- 2005-10-24 TN TNP2005000275A patent/TNSN05275A1/en unknown
- 2005-11-01 IL IL171721A patent/IL171721A/en active IP Right Grant
- 2005-11-01 KR KR1020057020706A patent/KR101076059B1/ko not_active Expired - Fee Related
- 2005-11-30 ZA ZA200509684A patent/ZA200509684B/en unknown
- 2005-11-30 NO NO20055652A patent/NO20055652L/no not_active Application Discontinuation
- 2005-12-01 MA MA28632A patent/MA27845A1/fr unknown
-
2006
- 2006-12-21 CY CY20061101847T patent/CY1105880T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR043670A1 (es) | Composicion farmaceutica que contiene lactato y usos de la misma | |
| AR054139A1 (es) | Formulacion modificada y de liberacion inmediata de esferas de memantina | |
| AR056055A1 (es) | Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno | |
| AR022076A1 (es) | Composicion antioxidante constituida por acetil l-carnitina y acido alfa-lipoico para mejorar el aprovechamiento metabolico de la glucosa | |
| AR047719A1 (es) | Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion que comprenden un ligando alfa-2-delta y un ssri y/o un snri | |
| DE122009000036I2 (de) | Verwendung von Dapoxetin, ein selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Dysfunktion | |
| CL2020000491A1 (es) | Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry. | |
| AR060264A1 (es) | Composicion farmaceutica que contiene lactato y calcio, usos de dicha composicion y metodo de preparacion | |
| PE20240885A1 (es) | Sales agonistas de sstr4 | |
| BRPI0414343A (pt) | combinações que compreendem ligantes de alfa-2-delta e inibidores da reabsorção de serotonina/noradrenalina | |
| AR045423A1 (es) | Combinaciones de analiticos y antidepresivos | |
| AR039977A1 (es) | Composicion a base de diclofenac para el tratamiento topico de afecciones de la cavidad orofaringea | |
| BR0209846B1 (pt) | utilizaÇço de um agente obtido pela irradiaÇço uv artificial de uma soluÇço aquosa para tratamento de esterilizaÇço de instrumentos mÉdicos. | |
| DE60335892D1 (de) | Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung und/oder fettleibigkeit im zusammenhang steht | |
| Raviña et al. | Hyperkalemia in fatal MDMA (‘ecstasy’) toxicity | |
| BRPI0413750A (pt) | uso de loxapina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica, e, kit | |
| AR069548A1 (es) | Sales de propionato de 3-(2,2,2- trimetilhidrazinio ) en el tratamiento de la enfermedad cardiaca isquemica y uso medico | |
| RU2006109966A (ru) | Препарат "янтастим-с" для терапии и профилактики инфекционных заболеваний животных | |
| RU2008150987A (ru) | Способ лечения переломов длинных трубчатых костей | |
| ES3034261T3 (en) | Amiselimod for use in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome | |
| RU2004116284A (ru) | Способ обработки костной полости после некрсеквестрэктомии | |
| MX2021016059A (es) | Uso de tasimelteón en el tratamiento de trastornos del sueño. | |
| AR023763A1 (es) | Agente que potencia la liberacion de acetilcolina en el cerebro | |
| MA28210A1 (fr) | Composition pharmaceutique contenant en association l'ubidecarenone, le dexpanthenol et le chlorhexidine ou leurs sels acceptables du point de vue pharmaceutique pour application cutanee | |
| DOP2003000657A (es) | Amidas de acidos 2-heteroarilcarboxilicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |